Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
wiki:user:jbaker [2012/10/01 00:09]
admin
wiki:user:jbaker [2014/05/13 21:00] (current)
stefan [Publications]
Line 1: Line 1:
 +~~NOTOC~~
 ====== Jennifer H. E. Baker ====== ====== Jennifer H. E. Baker ======
 +<WRAP column 50%>
 ==== Post Doctoral Fellow ====  ==== Post Doctoral Fellow ==== 
 +Supervisor, Dr. Stefan Reinsberg\\
 +Department of Physics & Astronomy, University of British Columbia\\
 +Office room Hennings 415\\
 +email: jbaker[at]bccrc.ca\\
 +\\
 +Funding provided by the Canadian Breast Cancer Foundation\\
 +{{:​cbcf-bcyukon-logo.jpg?​200|}}
 +</​WRAP>​
  
-{{ :​wiki:​user:​jheb.jpg?​200|}} +{{:​wiki:​user:​jheb.jpg?​200|}} 
-My research interests are in the tumour microenvironment,​ blood vessels, blood flow, drug distribution,​ MRI and hypoxia. My current main research focus is investigating the [[wiki:​research:​trastuzumab|heterogeneous distribution of trastuzumab in breast cancer using MRI and immunohistochemistry.]]+\\
  
-We use MRI and immunohistochemistry to examine functional and morphological features of the tumour microenvironment. We have developed custom tools that enable excellent correlation of MR and histologysuch that we can use the fine detail of many labeled features within the solid tumour to inform and validate observations made using MRI. Much of this work uses the custom scanning microscope and multiplex immunohistochemistry techniques developed in the [[http://​www.bccrc.ca/​dept/​ic/​radiation-biology-unit/​andrew-minchinton|Minchinton Lab]] at the BC Cancer Research Centre. A sample image of a Her2+ve xenograft is stained for systemically administeredunlabeled Herceptin (pink)CD31 vasculature (navy blue), perfusion dye (cyan blue), hypoxia ​(green), BrdU s-phase cells (black) and hematoxylin (grey)The tumour has a large area of necrosis (white) at the bottom where well-perfused skin is still attached to the tumour. The viable tumour tissue shows microregional heterogeneity:​ some regions have very little bound Herceptin around perfused blood vessels (top, right) whereas other regions have vessels with bound Herceptin several cell layers away from vessels (bottom, left & right). This tumour was collected 24h after a 10 mg/kg ip Herceptin treatment. + My research interests are in the tumour microenvironment, ​blood vesselsblood flowdrug distributionMRI and hypoxia. ​My current main research focus is investigating ​the [[wiki:research:trastuzumab|heterogeneous distribution of trastuzumab in breast cancer using MRI and immunohistochemistry.]]
-<​HTML>​ +
-<​br>​ +
-</​HTML>​ +
-{{panoview>:​wiki:user:ss071-5_compress.png?800 |}}+
  
-<​HTML>​ +We use MRI and immunohistochemistry to examine functional and morphological features of the tumour microenvironment. We have developed custom tools that enable excellent correlation of MR and histology, such that we can use the fine detail of many labeled features within the solid tumour to inform and validate observations made using MRI. Much of this work uses the custom scanning microscope and multiplex immunohistochemistry techniques developed in the [[http://www.bccrc.ca/​dept/​ic/​radiation-biology-unit/​andrew-minchinton|Minchinton Lab]] at the BC Cancer Research Centre. A sample image of a Her2+ve xenograft is stained for systemically administered,​ unlabeled Herceptin ​(pink), CD31 vasculature ​(navy blue), perfusion dye (cyan blue), hypoxia ​(green), BrdU s-phase cells (black) and hematoxylin (grey). The tumour has a large area of necrosis ​(whiteat the bottom where well-perfused skin is still attached to the tumourThe viable tumour tissue shows microregional heterogeneity:​ some regions have very little bound Herceptin around perfused blood vessels ​(top, right) whereas other regions have vessels with bound Herceptin several cell layers away from vessels (bottom, left & right). This tumour was collected 24h after a 10 mg/kg ip Herceptin treatment
-<​br>​ +<WRAP clear></WRAP> 
-<​br>​ +<WRAP column 550px
-<​br>​ +{{panoview>:​wiki:​user:​jbaker:​herceptin-image.jpg?​500x500|}} 
-</HTML> +</WRAP>
-==== Publications ==== +
-<​HTML>​ +
-<script language="​JavaScript"​ type="​text/javascript">​ +
-        function iFrameHeight(id+
-            var e = document.getElementById(id)+
-            var h = 0; +
-            if (!document.all+
-                h = e.contentDocument.height;​ +
-                e.style.height = h + 600 + '​px';​ +
-            } else if (document.all+
-                h = document.frames(id).document.body.scrollHeight;​ +
-                document.all.frames(id).style.height = h + 200 + '​px';​ +
-            } +
-        } +
-</​script>​ +
-<iframe id="​refbase-citations"​ name="​refbase-citations"​ onload="​iFrameHeight('​refbase-citations'​)" align="​top"​ width="​100%"​ height="​400px"​ scrolling="​auto"​ frameborder="​0"​ src="​http://​pfeifer.phas.ubc.ca/refbase/​show.php?​author=Baker&​amp;​without=dups&​amp;​submit=Cite&​amp;​citeOrder=year&​amp;​client=inc-refbase-1%2E0&​amp;​showLinks=1&​amp;​showRows=50"​ width="​100%"​ height="​500">​ +
-<p><a href="​http:​//​pfeifer.phas.ubc.ca/​refbase/​show.php?​author=Baker&​amp;​without=dups&​amp;​submit=Cite&​amp;​citeOrder=year&​amp;​client=inc-refbase-1%2E0&​amp;​showLinks=1&​amp;​showRows=50"​>view references</​a></​p+
-</iframe+
-</HTML>+
  
  
Print/export
QR Code
QR Code Jennifer H. E. Baker (generated for current page)